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Interleukin-5 (IL-5) is the key mediator for the func-
tion of eosinophil granulocytes, whose deregulation
is characteristic of hypereosinophilic diseases and
presumably contributes to allergic asthma. IL-5
signaling involves two transmembrane receptors,
IL-5Ra and the common b chain, which upon forma-
tion of the ternary complex activate the JAK/STAT
signaling cascade. To investigate the mechanism
underlying ligand-receptor recognition, we deter-
mined the structure of IL-5 bound to the extracellular
domain of IL-5Ra. IL-5 makes contact with all three
fibronectin III-like domains of IL-5Ra, with the
receptor architecture resembling a wrench. Muta-
genesis data provide evidence that this wrench-like
architecture is likely preformed. The structure
demonstrates that for steric reasons, homodimeric
IL-5 can bind only one receptor molecule, even
though two equivalent receptor-binding sites exist.
In regard to strong efforts being made to develop
IL-5 antagonists for treating asthma and hypereosi-
nophilic diseases, the advances in molecular under-
standing provided by this structure are of greatest
value.
INTRODUCTION
Eosinophilia syndromes represent a heterogeneous class of
disorders involving a largely increased number of eosinophils
in the peripheral blood and/or amassive infiltration of eosinophils
into certain tissues. This deregulation manifesting in the heart
(endomyocardial fibrosis or Loeffler’s endocarditis), brain,
gastrointestinal tract (eosinophilic gastrointestinal diseases), or
bone marrow results in tissue and organ damage (Klion, 2009).
It is the discharge of granular contents such as prostaglandins,
leukotrienes, and reactive oxygen-producing enzymes, all1864 Structure 19, 1864–1875, December 7, 2011 ª2011 Elsevier Ltdpowerful tools in the defense against worm pathogens, that
accounts for tissue fibrosis in this particular context (Kariyawa-
sam and Robinson, 2006). However, the above-mentioned
hypereosinophilic diseases are rare, but eosinophils’ actions
also seem to contribute to the pathology of asthma, character-
ized by airway obstruction and airway hyperresponsiveness to
antigens or nonspecific triggers, associated with increased
immunoglobulin production of the IgE class (atopy) (Kay,
2005). Although the extent to which eosinophils may contribute
to allergic asthma is still a matter of debate, their removal or
attenuation is nevertheless considered a valuable strategy to
counteract allergic asthma (Humbles et al., 2004; Lee et al.,
2004), opening the gates for therapeutic approaches involving
interleukin-5 (IL-5). As IL-5 controls many aspects of eosinophil
life from early differentiation of progenitor cells to migration,
proliferation, as well as activation and survival (Takatsu and Na-
kajima, 2008), it may not be surprising that in the past, various
routes have been developed to neutralize IL-5 activity such as
IL-5-neutralizing antibodies (Haldar et al., 2009), peptides that
compete for binding to the IL-5 receptor IL-5Ra (Ruchala et al.,
2004), or small molecules that bind to a free thiol group in the
extracellular domain of the IL-5Ra receptor, thereby blocking
IL-5 binding (Devos et al., 1994).
Interleukin-5 is a homodimeric cytokine whose typical four-
helix bundle is unusually intertwined and stabilized by two inter-
chain disulfide bonds (Milburn et al., 1993). It binds with high
affinity to the IL-5-specific IL-5Ra receptor. This intermediate
complex then recruits the common b (bc) receptor (CD130)
into a ternary complex. Similarly to receptor sharing observed
for many interleukin ligand-receptor systems, the bc receptor
is shared with interleukin-3 and granulocyte macrophage colony
stimulation factor (GM-CSF) (Tavernier et al., 1991). Mutagen-
esis studies performed on IL-5 and the receptor IL-5Ra have
provided fruitful insights into the epitopes as well as the
specificity of the underlying interaction (Cornelis et al., 1995;
Graber et al., 1995; Ishino et al., 2004; Tavernier et al., 1995),
but on a molecular or atomic level important details are missing
thus far due to the lack of structural data from IL-5 ligand-
receptor complexes. In this study, we present the high-resolu-
tion crystal structure of IL-5 bound to the extracellular domainAll rights reserved
Table 1. Data Collection and Refinement Statistics for the IL-
5:IL-5RaCM4 Complex Structure
Processinga
Space group P21
Unit cell a = 85.08 A˚, b = 61.64 A˚, c = 142.11 A˚
a = g = 90, b = 99.49
Wavelength (A˚) 0.9797 (peak) 0.9795
(inflection)
0.9079
(remote)
Resolution (A˚) 38.49–2.80
(2.90–2.80)
38.94–2.55
(2.64–2.55)
42.02–2.55
(2.64–2.55)
Rmerge 0.069 (0.438) 0.065 (0.458) 0.066 (0.684)
I/s I 8.2 (1.8) 8.5 (1.9) 8.2 (1.9)
Completeness (%) 99.5 (100.0) 99.7 (99.7) 99.9 (100.0)
Redundancy 2.12 (2.13) 2.44 (2.10) 2.53 (2.53)
Refinement
Resolution (A˚) 38.94–2.55 (2.62–2.55)b
Number of reflections 45,376 (3,296)
Rwork/Rfree (%) 21.0 (32.2)/26.4 (35.6)
Correlation coefficient
Fobs  Fcalc (Rfree)
0.934
B factor (Wilson plot) 81.9 A˚2
Coordinate error
(based on Rfree)
0.3 A˚
TLSc groups 10 (IL-5Ra: for each FNIII domain one TLS
group, residues 7–102, 103–214, 215–313;
IL-5: for each monomeric subunit, one TLS
group)
Number of atoms
Protein 8452
Water 55
Glucose 6
2,4-methylpentanediol 1
B factors
Protein (A˚2) 81.5
Water (A˚2) 70.7
Rmsds
Bond length (A˚) 0.019
Bond angle () 1.628
Torsion angle () 7.341
PROCHECK analysisd
Most favored region 87.5% (825 residues)
Additionally allowed
region
12.3% (112 residues)
Generously allowed
region
0.2% (2 residues)
Disallowed region 0% (0 residues)
aOne crystal was used to collect the diffraction data.
b Values in parentheses are for the highest-resolution shell.
c TLS, translation-libration-screw: modeling of translation, libration, and
screw-rotation movements of a pseudorigid body.
d Laskowski et al. (1993).
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Structure of IL-5 Bound to Its Receptor IL-5Raof its receptor IL-5Ra. In the complex, the extracellular domain
of the IL-5 receptor wraps around IL-5 like a wrench around
a nut. This new seemingly preformed receptor architecture hasStructure 19, 1864–18thus far only been seen for the rather distantly related cytokine
receptors IL-13Ra1 and IL-13Ra2 (LaPorte et al., 2008; Lupar-
dus et al., 2010). Despite these unanticipated structural similar-
ities between the IL-5 and IL-13 receptor ectodomains, the
ligand-binding mechanism differs significantly. The structure of
the IL-5:IL-5Ra complex also demonstrates that due to steric
hindrance, only one receptor moiety can bind to the homodi-
meric ligand IL-5 despite the presence of two equivalent
receptor-binding sites. In light of the strong efforts currently
being made to develop IL-5 antagonists for the treatment of
asthma and hypereosinophilic diseases, the structure now pro-
vides a detailed picture of the IL-5 ligand-receptor interactions
that will fuel the rational design particularly of small-molecule
IL-5 inhibitors.
RESULTS
Structure Analysis of the Binary Complex IL-5:IL-5Ra
To gain more insight into IL-5:IL-5R interaction, we prepared the
complex of IL-5 bound to the ectodomain of IL-5Ra. After purifi-
cation, the complex was crystallized and its structure was deter-
mined to 2.55 A˚ resolution (see Table 1). The electron density
map revealed two ligand-receptor complexes (A and B) in the
asymmetric unit (ASU). The receptor IL-5Ra is built from three
fibronectin type III (FNIII) domains (D1, D2, and D3), which could
be traced from Lys7 to Arg314 in complex A and from Ile8 to
Arg314 in complex B (Figure 1; see Figures S1 and S2 available
online). The ligand forms an intertwined dimer of two four-helix
bundles, with the fourth helix of each monomer (M1 and M2)
being swapped (Milburn et al., 1993). For both ligand molecules
in the asymmetric unit, IL-5 M1 could be traced from Thr3 to
Ile112 and from Pro6 to Glu114 for M2. In total, 8452 protein
atoms, six glucose molecules (three per complex), one 2-
methyl-2,4-pentanediol (in complex A), and 55 water molecules
(32 in complex A, 23 in complex B) could be identified.
The two complexes in the ASU superimpose almost perfectly
(root-mean-square deviation [rmsd] 1.1 A˚ for all Ca atoms, 1.6 A˚
for all heavy atoms), but some regions deviate significantly (Fig-
ure S3). The two IL-5Ra ectodomains differ in the b6b7 loop
(Gln83 to Leu88) of D1, with the loop being closer to IL-5 by
1.9 A˚ in complex A. However, as these residues are not in
contact with the ligand, these differences have probably only
a minor or no effect on ligand binding. Even larger is the differ-
ence for the IL-5Ra b1b2 loop (Asp121 to Ser128) of D2, whose
backbone shifts up to 8 A˚. In complex B this loop approaches IL-
5 Thr109 and Glu110 (IL-5 M2), whereas in complex A this loop
orients toward the solvent. In addition, the two IL-5 dimers in
the ASU exhibit conformational differences. The largest change
is observed for the N terminus and the N-terminal half of helix
a1 in IL-5 M1 (Glu4 to Glu13). Furthermore, changes are also
seen for the C terminus of helix a2, the a2a3 loop, and the start
of helix a3 of IL-5 M1 (Figure S3). Because the M1 subunit of IL-5
is not in contact with the receptor IL-5Ra, these changes likely do
not directly affect receptor binding.
The Ligand-Binding Domain of IL-5Ra Adopts
a Wrench-like Architecture
In the structure of the complex, the three FNIII domains 1 (amino
acids 7–101), 2 (amino acids 102–217), and 3 (amino acids75, December 7, 2011 ª2011 Elsevier Ltd All rights reserved 1865
Figure 1. Two IL-5:IL-5RaComplexes in the Asym-
metric Unit
(A) The asymmetric unit of the crystal contains two
complete IL-5:IL-5Ra complexes in a head-to-head
arrangement.
(B) Secondary structure elements in the ligand and
receptor components of the IL-5:IL-5Ra complex. The
subunits of the homodimeric IL-5 are shown in light and
dark gray; the three FNIII domains of IL-5Ra are shown in
blue (D1), green (D2), and red (D3). Secondary structure
elements are indicated.
See also Figures S1–S3.
Structure
Structure of IL-5 Bound to Its Receptor IL-5Ra218–314) of IL-5Ra wrap around the four-helix IL-5, figuratively
speaking, like a wrench around a nut (Figures 1 and 2). The
membrane-proximal D2 and D3 constituting the cytokine recog-
nition motif (CRM) domain share a 100 angle elbow, similar to
receptors such as IL-4Ra. Domains 1 and 2 are oriented in a 55
angle instead, resulting in a zigzag-like structure of the IL-5Ra
extracellular domain. Contact between IL-5 and the CRM of
IL-5Ra is mediated by the loops connecting the seven-stranded
b sheets of both FNIII domains, which gather in the hinge region
between D2 and D3. Although the structures of D1 and D3 are
almost identical, the contact of D1 with IL-5 is made via the
side of b strands 4 and 5 by rotating D1 about 30 out of plane
compared to D2 and D3. The main contacts of IL-5Ra with IL-5
are formed by the loops b2b3, b4b5, and b6b7 of D3, b3b4 and
b6b7 of D2, and strands b4 and b5 of domain D1 (Figures 1 and
2). Analysis reveals that although IL-5Ra covers almost 180 on
the IL-5 surface, the total buried surface area of IL-5Ra upon
binding to IL-5 (1150 A˚2) exceeds that by cytokine receptors
exhibiting only a two-FNIII domain CRM architecture such as
IL-4Ra (840 A˚2) (Hage et al., 1999) only by 27%. In the
complex, both IL-5 monomers of the symmetrical homodimer
form contacts with the receptor (Figures 1 and 2). The
C-terminal end of helix 3, the adjacent b strand 2, and helix 4
of subunit M1 contribute 760 A˚2 interface area, whereas helix
1, the loop ahead of helix 2, and the C terminus of the other
subunit M2 form 450 A˚2 of contact area with IL-5Ra. Comparing
the structures of free and receptor-bound IL-5 shows that
a large induced fit is absent (rmsd 1.2 A˚ for Ca atoms), suggest-
ing that most of the IL-5Ra epitope in IL-5 is preformed
(Figure S3).
IL-5Ra Shares the Wrench-like Architecture
with the IL-13 Receptors a1 and a2
The IL-5Ra receptor is one of the few known cytokine receptors
for which it is known that motifs apart from the CRM are essential
for ligand binding, with the structurally probably best investi-1866 Structure 19, 1864–1875, December 7, 2011 ª2011 Elsevier Ltd All rights reservegated example being gp130 of the IL-6 cytokine
family (Boulanger et al., 2003). Because amino
acid sequence homology among the cytokine
type I receptor family is quite low, we were
surprised that the ectodomain structures of IL-
5Ra and the IL-13 receptors IL-13Ra1 (LaPorte
et al., 2008) and IL-13Ra2 (Lupardus et al.,
2010) in their bound conformation in complex
with IL-4 and/or IL-13 are highly similar, espe-cially because the ligands IL-13/-4 and IL-5 differ vastly, with
IL-13 (as well as IL-4 as a ligand of IL-13Ra1) being a monomer
and IL-5 being a dimer (Figures 3A–3C). It is evenmore surprising
when the four-helix bundles of IL-5 and IL-13 are structurally
compared. Only helix D of both cytokine ligands, which makes
the largest contact with the receptor ectodomain, can be struc-
turally aligned (rmsd 0.5 A˚ for 13 Ca atoms); the interhelical
angles between other helices differ by more than 20. Further-
more, b strand 2 of the short b sheet is different in both ligands,
being longer and slightly differently oriented in IL-5 to make
larger contact with receptor domain 1. The structures of IL-
13Ra1 and IL-13Ra2 are, however, highly similar to IL-5Ra,
with the seven-stranded b sheets of the N-terminal D1 and D2
overlapping almost perfectly (Figure S4).
In contrast, gp130 receptor architecture is different, with the
complex consisting of IL-6, IL-6Ra, and gp130 assembling
into a heterohexameric structure (Figures 3D and 3E) (Boulanger
et al., 2003). Here, gp130’s second and third FNIII domains bind
to IL-6 similarly as seen in CRM-like receptor-ligand interaction
of other cytokine-receptor interactions such as IL-4:IL-4Ra
(Hage et al., 1999), IL-2:IL-2Rb (Wang et al., 2005), and
hGH:(hGHR)2 (de Vos et al., 1992) (Figure 3). FNIII domain 1 of
one gp130, however, ‘‘swaps’’ over to the second complex of
the hexameric ligand-receptor assembly contacting helix 1,
the a1a2 loop, and helix 4 of IL-6 (Boulanger et al., 2003). In
gp130 D1, mainly the N terminus, the b3b4 loop, and strand
b7 form the interface with IL-6. Additional stabilization derives
from the interaction of the b2b3 and b6b7 loops of gp130 D1
with the four-stranded b sheet in the IL-6Ra N-terminal FNIII
domain.
The molecular cause for the different architecture of IL-5Ra/
IL-13Ra1/IL-13Ra2 on the one hand and gp130 on the other
hand is probably due to differences in the linker between D1
and D2 (Figure 3F). The linker is conserved among IL-5Ra,
IL-13Ra1, and IL-13Ra2 with a consensus motif -Pro/Val-
Pro-X1-X2-(X)-Pro-X3-X4-X5-. Position X1 or X2 is filled by a Gly,d
Figure 2. The Architecture of the Binary IL-5:IL-5Ra Complex
(A) The three FNIII domains of IL-5Ra (D1, D2, and D3) bind to the homodimeric IL-5 (monomers IL-5M1, cyan and IL-5M2, light blue) with a wrench-like
architecture.
(B) As in (A), but rotated 90.
(C) IL-5Ra extracellular domain (D1, blue; D2, green; D3, red) covers more than 170 of the ligand four-helix bundle (gray).
(D) The IL-5 epitope of IL-5Ra (indicated by darker colors; in D1, dark blue; in D2, dark green; in D3, red).
(E) As in (D), but contact residues are color coded by polarity (acidic, red; basic, blue; polar, green; hydrophobic, gray).
(F) The IL-5Ra epitope in IL-5 (color as in D).
(G) As in (E), but for the receptor epitope in IL-5.
See also Figure S3.
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Structure of IL-5 Bound to Its Receptor IL-5Raand X3 to X5 are usually occupied by small residues. The 8-mer
stretch forms a U turn with the third Pro at the tip. Although the
linker of gp130 looks very similar, a comparison shows that it
is two residues shorter compared to IL-5Ra and IL-13Ra1. In
gp130, residues following the third Pro are already part of
b strand 1 in FNIII domain 2. Thus, all linker residues exhibit
backbone torsion angles characteristic for b sheets, whereas
corresponding residues -Pro-X3-X4- in IL-5Ra (Pro105-Gly106-
Thr107), IL-13Ra1 (Pro125-Glu126-Ser127), and IL-13Ra2
(Pro136-Glu137-Thr137) have torsion angles characteristic for
a-helical or turn-like structures. This feature allows D1 and D2
of IL-5Ra, IL-13Ra1, and IL-13Ra2 to fold on top of each other.
In contrast to this, the short linker of gp130 (Figure 3F) forces D1
and D2 to arrange in a linear manner. Attempts to vary the linker
in IL-13Ra1 by mutating individual residues (or increasing the
linker length) led to the loss of IL-13 binding (M. Kraich and
T.D.M., unpublished data).Structure 19, 1864–18Asymmetric Binding of the Receptor IL-5Ra to Its
Dimeric Ligand IL-5 Enforces a 1:1 Stoichiometry
The dimeric nature of IL-5 first suggests the existence of two
IL-5Ra epitopes. However, biochemical analyses revealed that
IL-5 and IL-5Ra interact with a 1:1 stoichiometry (Devos et al.,
1993). Consistently, an engineered monomeric IL-5 binds to
IL-5Ra, albeit with 40-fold lower affinity (Li et al., 1997). With
the structure, we can now assign a molecular reason for this
finding. Both IL-5Ra epitopes in the dimeric IL-5 molecule are
located face to face opposite of the two-fold symmetry axis of
IL-5 (Figure 4). However, one IL-5Ra bound to IL-5 already
covers parts on both sides of the two-fold axis. This results in
a steric clash with the b1b2 loop of IL-5Ra D2, which would
protrude far into D1 of a putative second IL-5Ra in a 1:2
IL-5:IL-5Ra model. Consequently, modeling of the complex of
IL-5 bound to its IL-5Ra and bc receptors based on the structure
of GM-CSF:GM-CSFRa:bc (Hansen et al., 2008) suggests75, December 7, 2011 ª2011 Elsevier Ltd All rights reserved 1867
Figure 3. Wrench-like Architecture Is
Shared between IL-5Ra and the IL-13
Receptors
(A–C) A ribbon plot of IL-5Ra bound to IL-5 (A), IL-
13Ra1 in complex with IL-13 and IL-4Ra (B), and
IL-13Ra2 bound to IL-13 (C) is shown, indicating
the remarkably similar structure of the receptor
ectodomains.
(D and E) Differences in the linker between D1
and D2 determine the receptor architecture. D1 of
gp130 does not fold back onto gp130’s CRM
formed by D2 and D3 (D) but is involved in
the assembly of a hexameric ligand-receptor
complex (E).
(F) A shortened linker between D1 and D2 of
gp130 prevents a similar wrench-like architecture.
Whereas a conserved sequence -Pro-Pro-small-
X-Pro- is observed in both IL-5Ra and gp130,
additional residues in IL-5Ra (marked in magenta)
allow D1 to fold over D2.
See also Figure S4.
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Structure of IL-5 Bound to Its Receptor IL-5Raa 2:2:1 stoichiometry of two (1:1) IL-5:IL-5Ra complexes bound
to one dimeric bc. In such a putative model of a ternary complex,
bc is located between two IL-5:IL-5Ra assemblies, with the
membrane-proximal D3 of IL-5Ra and bc D4 interacting with
each other (Figure 5). This model is also supported by biochem-
ical studies using an asymmetrically mutated single-chain IL-5
showing asymmetric receptor recruitment for IL-5Ra and bc
(Li et al., 1996). Remarkably, the contact between IL-5 and bc
would be comparably small. More than half of the surface of
IL-5 opposite the IL-5Ra-binding face would remain unburied
in the putative ternary assembly, raising the question of why
IL-5, unlike the other bc binders GM-CSF and IL-3, exists as
a dimeric molecule (Figure 5).
The IL-5Ra Structural Epitope Is Formed by Three
Independent Patches
Three IL-5-contacting patches can be identified in IL-5Ra: the
b2b3, b4b5, and b6b7 loops of D3, the b3b4 and b6b7 loops of
D2, and strands b3 and b4 of D1 (Figures 1 and 2; Figure S5).
In IL-5, interface residues cluster in the C terminus of helix a3,
b strand 2 between helices 3 and 4, which runs antiparallel to
b strand 4 of IL-5Ra D1, and helix 4 of monomer 1. In IL-5, M2
residues in the N-terminal half of helix 1, residues in b strand 1,1868 Structure 19, 1864–1875, December 7, 2011 ª2011 Elsevier Ltdand the C terminus contact IL-5Ra (Figures 1 and 2). Interactions
in patch 1 between b strand 2 inM1 of IL-5 and b strand 4 in D1 of
IL-5Ra are dominated by polar bonds, harboring 11 out of 15
total intermolecular hydrogen bonds (Figure 6A; Table S1). The
charge distribution between ligand and receptor is highly asym-
metric, resulting in strong charge-charge complementarities
between D1 of IL-5Ra and the IL-5 a3a4 loop (Figures S5 and
S6). Three consecutive residues, Arg90, Arg91, and Arg92,
form a positive patch in the a3a4 loop of IL-5, with Asp55,
Asp56, and Glu58 forming the complementary negative patch
in IL-5Ra. Besides IL-5 Arg91 forming a salt bridge with IL-5Ra
Asp55, other charged residues in the a3a4 loop of IL-5, Glu89,
Arg90, and Arg92 are also part of the H-bond network. The latter
act as a polar ‘‘zipper’’ forming eight direct intermolecular H
bonds with Ser64, Glu44, Glu58, Asp55, and Glu54 of IL-5Ra.
Four H bonds originate from Arg90 of IL-5, including a bidentate
main chain-main chain H bond to Glu58 of IL-5Ra and two salt
bridges between the guanidine group of Arg90 of IL-5 and the
carboxyl groups of Glu44 and Glu58 of IL-5Ra. Several of these
11 intermolecular H bonds are located at the solvent-accessible
interface surface, but their embedding in a large H-bond network
of 29 intra- and intermolecular H bonds possibly suggests a large
overall binding energy contribution. Interestingly, the structuralFigure 4. Steric Reasons Enforce the
Unusual 1:1 Receptor Stoichiometry of Ho-
modimeric IL-5
(A) Steric overlap of the two potential binding IL-
5Ra epitopes on IL-5. Both potential IL-5Ra
contact sites on IL-5 are shown as surfaces in blue
or light red with common residues shown in
magenta, thereby revealing strong steric overlap if
two receptor ectodomains would bind to a single
IL-5 molecule.
(B) As in (A), but rotated 90 around the y axis.
(C) The overlap is due to D2 of IL-5Ra, specifically
the long b1b2 loop.
All rights reserved
Figure 5. A Hetero-Octameric Assembly for
the Complex of IL-5 Bound to IL-5Ra and bc
(A) A model of IL-5 bound to IL-5Ra and the
dimeric bc on the basis of the ternary GM-CSF
ligand-receptor complex. No contacts are ob-
served between IL-5Ra D1 and bc.
(B) Due to the presence of two potential bc
epitopes in the dimeric IL-5, an alternative as-
sembly can be built in which bc is bound with the
two ectodomains placed side by side. However,
here no contacts between the membrane-prox-
imal FNIII domains as in (C) and (D) are observed,
and the C termini of IL-5Ra and bc are oriented in
an angle of 90 and are thus not pointing toward
the membrane, thereby rendering this assembly
highly unlikely.
(C and D) The ternary complex model presented
in (A) predicts a contact area of 1400 A˚2 between
the membrane-proximal FNIII domains of both
receptors (C) as well as several favorable H
bonds and hydrophobic interactions between the
membrane-proximal FNIII domains of IL-5Ra
and bc (D).
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Structure of IL-5 Bound to Its Receptor IL-5Rasimilarities in the wrench-like architecture between IL-5Ra and
IL-13Ra1/a2 are also reflected in a similar interaction of domain
1 of the IL-13 receptors with the ligand IL-13 (Figure S4). In the
complexes, b strand 4 of the receptors and the ligands’ b strand
2 all share a main chain-main chain H bond; various additional
polar bonds strengthen this conserved interaction, possibly via
a cooperative mechanism. However, there are far fewer polar
bonds between D1 of IL-13Ra1/a2 and the ligand IL-13
compared to the IL-5:IL-5Ra interaction. Furthermore, the
‘‘affinity-maturated’’ IL-13Ra2, which exhibits a drastically
increased affinity to IL-13, does not form an increased number
of intermolecular H bonds with IL-13 via D1. It seems that here
the affinity is increased due to more hydrophobic and polar inter-
actions in site II equivalent to patch 2.
Patch 2 consists of D2 (b3b4 and b6b7 loops) of IL-5Ra, which
interacts with the a1a2 loop and the C terminus of IL-5 M2
(Figures 1, 2, and 6B). Although several residues are of polar or
charged character, only one H bond exists between IL-5 Lys39
and the backbone of Arg188 of IL-5Ra. Arg188 of IL-5Ra was
suggested to be important for IL-5 binding (Ishino et al., 2004);
however, it is not only the polar character but also the hydro-
phobic interaction of the Arg188 side chain with Val106 and
Thr109 of IL-5 that contributes to binding. Its positive charge is
neutralized by Glu110 of IL-5 M1, which was identified as
amain binding determinant of IL-5 (Morton et al., 1995), but there
is no H bond between IL-5 Glu110 and IL-5Ra Arg188. Thus, as
Arg188 is completely buried inside the interface, loss of the
negative charge possibly leads to repulsive electrostatic forces.
Another hydrophobic binding determinant is IL-5Ra Trp158 in
the b3b4 loop, which contacts Trp111 and Ile112 of IL-5 M1.
Because most intermolecular interactions in patch 2 are medi-Structure 19, 1864–1875, December 7, 2011 ªated only by side chain-side chain
contacts, patch 2 seems less tightly
packed compared to patch 1.
Patch 3 comprises D3 of IL-5Ra,
namely the b2b3, b4b5, and b6b7 loops,which pack against the C-terminal half of helix 4 of IL-5 subunit
M1 and helix 1 of IL-5 subunit M2 (Figures 1, 2, and 6C). Patch
3 adds the least buried surface area (276 A˚2 of IL-5Ra and
430 A˚2 of IL-5), and it might thus be assumed that it contributes
less to the overall binding energy. Indeed, a truncated IL-5Ra
lacking D3 still binds weakly to IL-5, whereas deletion of D1 in
IL-5Ra abrogates IL-5 binding completely (data not shown).
Most interactions here are hydrophobic (Figures 1, 2, and 6C).
The C-terminal half of IL-5 M1 helix 4 packs against a hydro-
phobic area in IL-5Ra, with the disulfide bond between Cys249
and Cys296 in the center. Interestingly, IL-5Ra Arg297,
a proposed hot spot of IL-5 binding (Ishino et al., 2004), makes
almost no contact with IL-5. Its importance for binding is due
to an intramolecular salt bridge with IL-5Ra Asp217, thereby
stabilizing the hinge angle between D2 and D3. Mutation of
Arg297 might affect the orientation of both domains, leading to
loss of binding.
The Functional Ligand-Receptor Epitope
of the IL-5:IL-5Ra Complex
Previous mutagenesis studies revealed several residues of IL-5
and IL-5Ra that are functionally important for the interaction
(Figures 6D and 6E). The early studies performed by the groups
of Jan Tavernier and Walter Fiers at Roche (Cornelis et al., 1995;
Tavernier et al., 1995) and Timothy Wells at Glaxo (Graber et al.,
1995) did not employ surface plasmon resonance or calorimetry
to determine the energy contribution. However, their results
derived from cell-based binding assays, proliferation, or compe-
tition binding analysis clearly identifiedGlu89, Arg91, and Trp111
as main binding determinants of IL-5 and His38, Lys39, His41,
Thr109, and Glu110 as of significant but minor importance for2011 Elsevier Ltd All rights reserved 1869
Figure 6. Three Patches Define the Struc-
tural Binding Epitopes in IL-5Ra and IL-5
(A) H bonds (stippled lines in magenta) dominate
the interaction between IL-5RaD1 (C atoms, cyan)
and IL-5 (C atoms in IL-5M2, green and in IL-5M1,
light green; the latter residues are marked by an
asterisk).
(B) The interaction between IL-5Ra D2 and IL-5 is
mediated by hydrophobic contacts shown as
spheres.
(C) van der Waals interactions between IL-5Ra D3
and IL-5.
(D) Functional epitope of IL-5Ra. Energetic
contributions determined from mutagenesis and
binding assays are color coded on the IL-5Ra
surface. Red residues contribute R2.5 kcal/mol,
residues in orange show a loss of R1 kcal/mol
upon mutation, and residues in yellow contribute
between 0.5 and%1 kcal/mol to IL-5 binding. Blue
residues do not alter the affinity upon mutation to
alanine.
(E) Functional epitope of IL-5, with color coding as
in (D). Residues marked by an asterisk are located
in IL-5 monomer M1.
See also Figures S5 and S6 and Tables S1–S3.
Structure
Structure of IL-5 Bound to Its Receptor IL-5RaIL-5Ra binding (Table S2; Figure 6E). Based on the structure, it
now becomes evident that IL-5 His38, His41, and Trp111 seem
to stabilize the structure or ‘‘orient’’ side chains of other residues
in IL-5, thereby contributing to binding IL-5Ra. His38 and His41
help to stabilize the IL-5 a2a3 loop and orient Lys39, which
then interacts via an H bond with the carbonyl of IL-5Ra
Arg188. Similarly, IL-5 Trp111 is important for the structural
integrity of the C terminus of helix 4. Nonconservative exchanges
likely lead to local unwinding, thereby destroying favorable inter-
actions of the nearbyGlu110 and of van derWaals interactions of
helix 4 with the b6b7 loop of IL-5Ra D3 (Figure 6C).
Several studies also analyzed the role of important residues in
IL-5Ra (Cornelis et al., 1995; Ishino et al., 2004) showing that
polar bonds dominate the interaction between IL-5Ra D1 and
IL-5. Alanine mutagenesis of the two main binding determinants
Asp55 (KD 156-fold increased) and Asp56 (KD 17-fold increased
(Ishino et al., 2004) destroys the H-bond network with Arg91 and
Gln95 (both to Asp55 of IL-5Ra) as well as Arg32 and Arg92 (to
Asp56 of IL-5Ra) of IL-5. Our data (Table S3) show that maintain-
ing the negative charge in the variant D55E partially attenuates
the loss of binding (KD 14-fold increased). The main chain-main
chain H bond between Glu58 of IL-5Ra and Arg90 of IL-5 is
conserved in the interaction between IL-4/IL-13 and IL-13Ra1
(Figure S4) and is absolutely crucial for binding (IL-5Ra E58P
KD R2000-fold increased). In contrast, H bonds between their
side chains do not contribute significantly (Ishino et al., 2004).
Tyr57 of IL-5Rawas also identified as a hot spot of binding (Cor-
nelis et al., 1995). Exchange to alanine leads to an almost
complete loss of binding. This large effect can be explained by
favorable p-p stacking interactions of the aromatic ring and
the guanidine group of IL-5 Arg91, which possibly stabilize the
salt bridge between IL-5 Arg91 and IL-5Ra Asp55 (Figure 6A).
Accordingly, replacement of Tyr57 by phenylalanine does not
decrease IL-5 affinity significantly (4.5-fold). The highly coopera-
tive H-bond network is exemplified by the alanine replacement of1870 Structure 19, 1864–1875, December 7, 2011 ª2011 Elsevier LtdIL-5Ra Ser64 (60-fold loss in affinity), which coordinates the
orientation of IL-5Ra Tyr57 as well as IL-5 Glu89, which interacts
with IL-5 Arg91.
Outside IL-5Ra D1, very few residues are described that play
a role in the IL-5:IL-5Ra interaction (Table S3; Figure 6D). Ishino
et al. (2004) identified Arg188 in IL-5Ra D2 as a main binding
determinant. Further contribution to IL-5 binding comes from
Lys186 (D2) and Arg297 (D3). However, only IL-5Ra Lys186
engages in an H bond with IL-5 Glu110, whereas IL-5Ra
Arg188 shares hydrophobic contacts with Gly105, Val106, and
Thr109 of IL-5. Additionally, through its intramolecular H bond
with the carbonyl of Cys296, Arg188 likely orients the IL-5Ra
D3 b6b7 loop.Mutation of Arg188 to lysine thus results in a similar
reduction in affinity as for R188A, as the shorter side chain results
in the loss of this H bond. Arg297 of IL-5Ra acts similarly, as it
makes no contact with IL-5, but also stabilizes the IL-5Ra D3
b6b7 loop via an intramolecular H bond with Asp217.
As there are almost no intermolecular H bonds involving the
side chains of D2 and D3 of IL-5Ra, it seems that contribution
of the polar residues by their side chains to IL-5 binding is limited
(Table S3; Figure 6D). However, the number of hydrophobic
contacts between IL-5Ra and IL-5 making favorable van der
Waals contacts is also small. Only Trp158 and Met295 of
IL-5Ra share significant contact area. Mutation W158A reduces
the affinity for IL-5 19-fold, and M295A decreases the affinity
9-fold. Further van der Waals contacts in the interface involve
the main chain of IL-5Ra, thereby highlighting the importance
of residues (Ile183, Arg297) that maintain the receptor loop
conformation.
The Wrench-like Architecture of IL-5Ra Is Possibly
Preformed
The structure of IL-5Ra raises the question of whether its archi-
tecture is preformed or whether the ‘‘wrench’’ closes only upon
binding to IL-5 (Figure 7A). The contact of IL-5 with all FNIIIAll rights reserved
Figure 7. The Wrench-like Architecture of IL-5Ra Is Likely Preformed
(A) Overview of the IL-5:IL-5Ra complex.
(B) Conserved residues in IL-5Ra D1 (C atoms, blue) and D2 (C atoms, green) possibly fix the domain orientation in IL-5Ra. H bonds are shown as stippled lines;
hydrophobic contacts are indicated by van der Waals spheres.
(C) A similar interface between D1 and D2 is conserved in IL-13Ra1.
(D) Mutation of the hydrophobic contact involving Ile69 of IL-5Ra strongly attenuates ligand-binding affinity. This affinity decrease is due to a slower association
rate kon, indicating that formation of the wrench-like architecture is possibly the rate-limiting step in complex formation.
Structure
Structure of IL-5 Bound to Its Receptor IL-5Radomains of IL-5Ra covers more than 170 of the IL-5 torus, and
thus opening and closing of the wrench would on the one hand
facilitate complex formation; on the other hand, several observa-
tions also argue against a ligand-induced opening/closing
mechanism. First, residues in the D1-D2 interface are conserved
in IL-5Ra of different species as well as in the structurally related
receptors IL-13Ra1 and IL-13Ra2 (Figures 7B and 7C). Second,
replacement of one of the conserved residues in the linker region
of IL-13Ra1 (see above) or changing the length of the linker abro-
gated binding of IL-13 completely (M. Kraich and T.D.M., unpub-
lished data). We thus mutated several residues that either share
hydrophobic contacts or are involved in H bonds between D1
and D2. Four residues seem to occupy key positions: Leu23,
Ile69, and His71 in D1 and Asp208 in D2 of IL-5Ra (Figure 7B).
Residue Asp208 in b strand 8 of D2 is completely buried in the
D1-D2 interface. Its carboxylate group forms two H bonds with
the amides of Leu70 and His71 (in D1). Because Asp208 is
completely shielded by Leu23, Ile69, and His71 of D1 and
Leu194, Pro206, and Leu210 of D2, these H bonds presumably
(help to) orient D1 and D2 (Figure 7B). Mutation of any of these
residues should thus disrupt the architecture, thereby abro-
gating binding. Indeed, mutations L23A and D208A abrogate
IL-5 binding completely, whereas IL-5Ra H71A could not even
be refolded. Estimating the KD on the basis of the upper surface
plasmon resonance measurement limits suggests a KD for L23A
or D208A larger than 5mM. Thus, the affinity is decreased at least
2500-fold (Table S3). Exchange of IL-5Ra Ile69 to alanine has the
‘‘smallest’’ impact, with a 550-fold affinity loss. The loss of IL-5
binding due to mutations in the IL-5RaD1-D2 interface suggests
that either the ligand binding via an initially open wrench archi-
tecture is highly cooperative with the interactions between IL-
5Ra D1 and the ligand on one side and the interactions in the
D1-D2 interface being coupled or that the wrench is preformed
and destabilization of this ‘‘closed’’ architecture leads to the
observed loss of IL-5 binding. However, together with the obser-Structure 19, 1864–18vation that changes in the linker also lead to loss of ligand binding
in IL-13Ra1, another piece of experimental evidence hints to the
latter mechanism of a preformed wrench architecture. The
decrease in affinity observed for I69A is solely due to a strongly
reduced association rate kon (kon(var.)/kon(WT) = 2.7 3 10
3),
whereas the dissociation rate koff is unaltered (koff(var.)/koff(WT) =
1.5) (Figure 7D). The slower association might be explained by
the opening and closing of the destabilized wrench being the
rate-limiting step of IL-5 binding and much slower than it would
be via a preformed wrench architecture. The almost unaltered
dissociation rate points toward the complex stability (i.e., the
complex lifetime) being the same as for the wild-type proteins
and that the D1-D2 interface interactions are likely not just
contributing in a cooperative binding mechanism. However, to
finally solve this puzzle, structural data for the unbound ectodo-
main of IL-5Ra are needed.
DISCUSSION
IL-5 and GM-CSF belong to the cytokine family sharing the bc
receptor, and their a receptors show reasonable amino acid
sequence homology. Recently, the structure of the ternary
ligand-receptor complex GM-CSF:GM-CSFRa:bc has been
determined (Hansen et al., 2008). In this structure, a large part
of the receptor GM-CSFRa is unstructured and not modeled
(Figure 8A). In the structure, only GM-CSFRa FNIII domain 3
from Phe196 to Gly294 is ordered. For D2 only a small part is
observed, including a two-stranded b sheet corresponding to
strands 1 and 2 and a short structure matching the b6b7 loop
of IL-5Ra D2. Domain 1 is completely absent from the model
(in Hansen et al., D1 is called the ‘‘knob’’ and D2 and D3 are
numbered D1 and D2, respectively). SDS-PAGE analysis of
crystals proved the presence of the full ternary complex with
all components seemingly intact. Thus, Hansen et al. concluded
that D1 of GM-CSFRawould be disordered. This is in contrast to75, December 7, 2011 ª2011 Elsevier Ltd All rights reserved 1871
Figure 8. The Receptor a Chains of the bc Family Likely Share a Similar Wrench-like Architecture
(A) The GM-CSFRa ectodomain (D2, green; D3, red) is only partially observed in the structure of GM-CSF:GM-CSFRa:bc (monomers, yellow and brown).
(B) Molecular model of GM-CSFRa (D1, blue; D2, green; D3, red) built from IL-5Ra likely sharing the same architecture.
(C) Similar disulfide pattern predicted in GM-CSFRa. Structure alignment of GM-CSFRa (model) and IL-5Ra (left) as well as of GM-CSFRa and IL-13Ra1 (right)
shows the similar arrangement of the FNIII domains in the receptor ectodomains, with disulfide bonds in D2 highly conserved and disulfides in D1 and D3
occupying similar locations.
(D) Similar polar interactions between D1 and the ligand are predicted for the model of GM-CSFRa and GM-CSF.
See also Figure S7.
Structure
Structure of IL-5 Bound to Its Receptor IL-5Rathe highly defined wrench architecture of IL-5Ra with all three
domains in tight contact with the ligand (Figures 1 and 2). One
conclusion would be a diversity in the architectures of the
a subunits of bc cytokine family members IL-3Ra, GM-CSFRa,
and IL-5Ra regardless of the similarities in sequence.
However, a sequence alignment (Figure S7) of these receptor
ectodomains together with IL-13Ra1 (LaPorte et al., 2008) shows
that the sequences encoding the b strands in the three FNIII
domains are conserved, suggesting a similar secondary struc-
ture in GM-CSFRa and IL-3Ra (Figures 8A and 8B). Furthermore,
D1 of GM-CSFRa contains five cysteines presumably involved in
disulfide bridges, arguing against intrinsic disorder. From the
sequence alignment we modeled disulfide bonds for GM-
CSFRa, suggesting disulfides between Cys29 and Cys65, and
Cys38 and Cys57, in D1 (Figure 8C). Based on this model
Cys59 would be unpaired, possibly sharing a similar role with
Cys66 in IL-5Ra. Several favorable interactions could be pre-
dicted between the modeled D1 of GM-CSFRa and GM-CSF.
The distribution of charged residues in the putative ligand inter-
face of D1 of GM-CSFRa (mainly positively charged amino acids,
e.g., Lys44 and Arg46) and helix 4 of GM-CSF (negatively
charged amino acids, e.g., Glu104 and Glu108) would also
support a ligand-receptor architecture as in IL-5:IL-5Ra (Fig-
ure 8D). Moreover, the interface between D1 and D2 (see above),
which likely preforms the wrench-like architecture (see above), is1872 Structure 19, 1864–1875, December 7, 2011 ª2011 Elsevier Ltdconserved in IL-5Ra, GM-CSFRa, and IL-3Ra. The aspartate
residue in D2 (Asp208 in IL-5Ra), which possibly orients D1 and
D2 byHbonds, is conserved inGM-CSFRa (Asp185) and IL-3Ra.
Very recent mutagenesis data support the assumption for
a common architecture of the receptor a subunits IL-3Ra,
IL-5Ra, and GM-CSFRa (Mirza et al., 2010). Mutation of Val51,
Arg54, and in particular Cys59 in GM-CSFRa abrogates
GM-CSF binding. Similarly, deletion of D1 in IL-3Ra and the
GM-CSFRa/IL-3Ra chimera have shown that N-terminal D1 is
required for high-affinity binding of IL-3 and that corresponding
residues of GM-CSFR cannot substitute (Barry et al., 1997;
Rapoport et al., 1996). Whether the ternary complex formation
triggers a rearrangement in the interdomain architecture cannot
be answered at present. However, the structure of IL-13Ra1
(and of IL-13Ra2) in the complexes bound to the monomeric
cytokine IL-4 or IL-13 (LaPorte et al., 2008; Lupardus et al.,
2010), which is highly similar to IL-5Ra (Figure 3; Figure S4),
suggests that the wrench-like architecture does not arise from
the unique homodimeric nature of IL-5.
Although the role of eosinophils in asthma is still under debate
(Nair et al., 2009; Wenzel, 2009), the attenuation of symptoms in
hypereosinophilic diseases upon removal of eosinophils by
approaches targeting IL-5 clearly fortifies IL-5 as an interesting
and important drug target for such endeavors (Rothenberg
et al., 2008). With the aid of the structure of the IL-5:IL-5RaAll rights reserved
Structure
Structure of IL-5 Bound to Its Receptor IL-5Racomplex, small-molecule- and peptide-based inhibitors that
impede IL-5 binding to IL-5Ra can be rationally designed. For
the cyclic peptide AF17121, an IL-5-inhibiting mechanism was
proposed assuming the structural similarity of this peptide to
the IL-5 a3a4 turn (Ruchala et al., 2004). However, that several
residues of this peptide lack similarity with IL-5 but are never-
theless important for interaction suggests that its binding to
IL-5Ra is more complex. Isothiazolone derivatives inhibit IL-5
signaling by covalent modification of the free thiol of Cys66 in
IL-5Ra (Devos et al., 1994). Our own studies show that small
thiol-reactive compounds such as mercaptoethanol are toler-
ated in ligand binding. Cys66 is located within the interface in
a water-filled pocket with a 6–7 A˚ gap to IL-5, thereby explaining
why only larger compounds inhibit IL-5 binding efficiently. Also,
small IL-5-inhibiting compounds that do not interfere via
covalent attachment to Cys66 could be identified. Whereas for
inhibitory isoflavones and chalcones the inhibition mechanism
cannot be linked to direct binding to either IL-5Ra or IL-5 (Min
et al., 1999; Yang et al., 2007), a quinoxaline derivative,
YM-90709, has been shown to directly interfere with the
IL-5:IL-5Ra interaction and block receptor activation with a
submicromolar IC50 (Morokata et al., 2002). However, no molec-
ular details of this interaction are known thus far. The new
structure of the IL-5:IL-5Ra complex thus now provides the
necessary insights into the ligand-receptor recognition and will
likely facilitate rational design to improve anti-IL-5 therapeutics
for their application in the treatment of allergic asthma and
hypereosinophilic diseases.EXPERIMENTAL PROCEDURES
Preparation of Human IL-5
Human IL-5 was expressed and purified from Escherichia coli as described
(Proudfoot et al., 1990). IL-5 was extracted from inclusion bodies and prepuri-
fied by gel filtration using 6 M guanidine hydrochloride, 10 mM sodium acetate
(pH 4.5) as running buffer before renaturation. The IL-5 protein was subse-
quently refolded by a multistep protocol as described (Proudfoot et al.,
1990). After refolding, the protein was concentrated to 5 mg/ml and purified
by gel filtration using a HiLoad 16/60 Superdex column. IL-5 variants were
prepared using QuikChange methodology (Stratagene). The correctness of
the IL-5 mutant proteins was verified by sequencing of the expression plasmid
cDNA and subsequently on a protein level by electrospray ionization Fourier
transform ion cyclotron resonance mass spectrometry.
Preparation of the Extracellular Domain of Human IL-5Ra
The soluble splice variant of human IL-5Ra comprising Asp1 to Arg314 was
cloned into the pET3d vector and expressed in the E. coli strain Rosetta(DE3)
by a modified protocol (Monahan et al., 1997; Murata et al., 1992). IL-5Ra was
isolated from inclusion bodies. For refolding, denatured IL-5Ra was diluted
with refolding buffer consisting of 7.5 M urea, 50 mM Tris-HCl (pH 9.5),
0.1 mM cysteine to a concentration of 100 mg/ml. First, this refolding solution
was dialyzed against 10 volumes of 3Murea, 50mMTris-HCl (pH 9.5), 100 mg/l
CuSO4 for 24 hr. The urea concentration was then lowered every 24 hr by
exchanging 50% of the dialysis buffer with 50 mM Tris-HCl (pH 9.5) until
a urea concentration of 0.75 M was obtained. Refolding was stopped by
dialysis against 50 mM Tris-HCl (pH 8.1). IL-5Ra was purified by anion-
exchange chromatography (Q-Sepharose) using a linear gradient from 0 to
0.5 M NaCl in 50 mM Tris-HCl (pH 8.1). Dimeric IL-5Ra and higher-molec-
ular-weight aggregates were removed by affinity chromatography using an
IL-5 affinity matrix. Variants were prepared using the QuikChange method-
ology (Stratagene), and mutations were verified by DNA sequencing. Purity
and homogeneity of IL-5Ra proteins were analyzed by SDS-PAGE, analytical
reverse-phase HPLC, and mass spectrometry.Structure 19, 1864–18Preparation and Crystallization of the Binary Ligand-Receptor
Complex IL-5:IL-5Ra
The complex of IL-5:IL-5Ra was prepared by mixing the proteins at an equi-
molar ratio and subsequent gel filtration using 10 mM Tris-HCl (pH 8.1),
150 mM NaCl as buffer. Fractions containing the complex were combined
and concentrated to 10 mg/ml in 10 mM Tris-HCl (pH 8.1). Crystals were ob-
tained by vapor diffusion (sitting- or hanging-drop) from various conditions
of commercial kits (e.g., Hampton crystal screens 1 and 2, PEG/ion screen,
as well as JBS screens 4 and 5 of Jena Bioscience). All of the initial crystalliza-
tion conditions were unsuitable for data collection due to needle cluster
formation. Mutating Cys66 of IL-5Ra to alanine improved reproducibility
and yielded single crystals. Final additive screening and optimization of the
crystallization buffer composition provided crystals of suitable size (400 3
200 3 50 mm) growing from 10% PEG 20000, 20% glucose, 0.1 M MOPS
(pH 6.5), 2.5% 2,4-methylpentanediol using a hanging-drop setup and a
protein:precipitant ratio of 1:1 in the droplet within 3–5 days.
Data Collection and Structure Determination
We solved the structure using a seleno-multiwavelength anomalous dis-
persion approach. To increase the number of methionine residues, four
mutations were introduced into IL-5RaC66A: K72M, L138M, K167M, and
L234M, referred to as IL-5RaCM4. SeMet-derivatized IL-5 and IL-5RaCM4
were prepared by expression in E. coli B834(DE3), which were grown in
M9minimalmedium supplementedwith 50mg/l DL-selenomethionine. Protein
purification, complex preparation, and crystallization were performed as
described above. Anomalous data were acquired at 100K at three wave-
lengths from a single crystal of Se-IL-5:Se-IL-5RaCM4 (peak, inflection, and
remote) using beamline XS10 SA (Swiss Light Source, Switzerland) and
a 235 sweep with a 1 s exposure per frame and a 1 oscillation. Diffraction
data were complete to a resolution of 2.55 A˚ for peak and remote and to
2.8 A˚ for the inflection wavelength. Data were processed using CrystalClear
(Rigaku), seleno-atom positions were determined using SHELX (Sheldrick,
2008), and refinement and phasing were performed using SHARP/autoSHARP
(Vonrhein et al., 2007). The initial experimental electron density map was
traced automatically using ARP/WARP (Perrakis et al., 1999) to provide an
initial template for manual model building. Refinement was completed using
experimental phases throughout refinement and REFMAC version 5.02 (Mur-
shudov et al., 1997) (for statistics, see Table 1).
Surface Plasmon Resonance Analysis
Surface plasmon resonance experiments were performed using a Biacore
2000 system (GE Healthcare). Data were evaluated using the software
BIAevaluation (version 2.2.4). All measurements were performed at 294K using
HBS150 buffer (10 mMHEPES [pH 7.4], 150 mMNaCl, 3.4 mM EDTA, 0.005%
surfactant P20). A CM5 sensor chip was coated with about 3000 resonance
units (1 RU = 1 pg mm2) streptavidin (Sigma) by amino coupling using N-
hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. For
immobilization, IL-5 was biotinylated with a 2-fold molar excess (protein:biotin)
of NHS-LC-biotin (Pierce) according to the manufacturer’s recommendation
and then captured on the streptavidin chip to a density of maximal 300 RU.
To analyze binding, six different analyte concentrations were used, usually
ranging from 0.13 to 103 of the KD value determined in the experiment.
Bulk effects were corrected by subtracting a sensorgram of a control flow
cell from all other sensorgrams. The biosensor was regenerated by application
of a short pulse (30 s) of 4MMgCl2. The data were fitted to a 1:1 Langmuir-type
interactionmodel, and the KD valueswere calculated from the fitted kinetic rate
constants kon (association rate) and koff (dissociation rate). All affinities are
termed ‘‘apparent’’ KDs, indicating that the absolute values might differ from
values obtained by other methods. However, in a direct comparison of values
obtained under these conditions, a difference of more than 2-fold is consid-
ered significant.ACCESSION NUMBERS
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